Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
86 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Regeneron Pharmaceuticals, Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Regeneron Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Regeneron Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Regeneron Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Regeneron Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Regeneron Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Regeneron Pharmaceuticals, Inc.'s pipeline products Reason to Buy - Evaluate Regeneron Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Regeneron Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Regeneron Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Regeneron Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Regeneron Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Regeneron Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Regeneron Pharmaceuticals, Inc. Snapshot 6 Regeneron Pharmaceuticals, Inc. Overview 6 Key Information 6 Key Facts 6 Regeneron Pharmaceuticals, Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 Regeneron Pharmaceuticals, Inc. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 Pipeline Products - Partnered Products 13 Partnered Products/Combination Treatment Modalities 14 Regeneron Pharmaceuticals, Inc. - Pipeline Products Glance 15 Regeneron Pharmaceuticals, Inc. - Late Stage Pipeline Products 15 Pre-Registration Products/Combination Treatment Modalities 15 Phase III Products/Combination Treatment Modalities 16 Regeneron Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 17 Phase II Products/Combination Treatment Modalities 17 Phase I Products/Combination Treatment Modalities 18 Regeneron Pharmaceuticals, Inc. - Early Stage Pipeline Products 19 Preclinical Products/Combination Treatment Modalities 19 Regeneron Pharmaceuticals, Inc. - Drug Profiles 20 aflibercept (recombinant) 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 alirocumab 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 dupilumab 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 sarilumab 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 ziv-aflibercept (recombinant) 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 evinacumab 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 rinucumab 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 trevogrumab 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 REGN-19081909 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 (aflibercept + nesvacumab) 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 nesvacumab 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 REGN-1154 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 REGN-1193 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 REGN-1400 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 REGN-1979 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 REGN-2222 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 REGN-2810 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 REGN-1001 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Regeneron Pharmaceuticals, Inc. - Pipeline Analysis 51 Regeneron Pharmaceuticals, Inc. - Pipeline Products by Target 51 Regeneron Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 53 Regeneron Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 54 Regeneron Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 55 Regeneron Pharmaceuticals, Inc. - Recent Pipeline Updates 57 Regeneron Pharmaceuticals, Inc. - Dormant Projects 78 Regeneron Pharmaceuticals, Inc. - Discontinued Pipeline Products 79 Discontinued Pipeline Product Profiles 79 dapiclermin 79 enoticumab 79 nesvacumab 79 REGN-2009 79 REGN-728 79 REGN-846 80 rilonacept (recombinant) 80 Regeneron Pharmaceuticals, Inc. - Company Statement 81 Regeneron Pharmaceuticals, Inc. - Locations And Subsidiaries 83 Head Office 83 Other Locations & Subsidiaries 83 Regeneron Pharmaceuticals, Inc. - Key Manufacturing Facilities 84 Appendix 85 Methodology 85 Coverage 85 Secondary Research 85 Primary Research 85 Expert Panel Validation 85 Contact Us 85 Disclaimer 86
List of Tables
Regeneron Pharmaceuticals, Inc., Key Information 6 Regeneron Pharmaceuticals, Inc., Key Facts 6 Regeneron Pharmaceuticals, Inc. - Pipeline by Indication, 2015 8 Regeneron Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 10 Regeneron Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 11 Regeneron Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2015 12 Regeneron Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2015 13 Regeneron Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 14 Regeneron Pharmaceuticals, Inc. - Pre-Registration, 2015 15 Regeneron Pharmaceuticals, Inc. - Phase III, 2015 16 Regeneron Pharmaceuticals, Inc. - Phase II, 2015 17 Regeneron Pharmaceuticals, Inc. - Phase I, 2015 18 Regeneron Pharmaceuticals, Inc. - Preclinical, 2015 19 Regeneron Pharmaceuticals, Inc. - Pipeline by Target, 2015 52 Regeneron Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015 53 Regeneron Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015 54 Regeneron Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015 56 Regeneron Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015 57 Regeneron Pharmaceuticals, Inc. - Dormant Developmental Projects,2015 78 Regeneron Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015 79 Regeneron Pharmaceuticals, Inc., Other Locations 83 Regeneron Pharmaceuticals, Inc., Subsidiaries 83 Regeneron Pharmaceuticals, Inc., Key Manufacturing Facilities 84
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
